Theriva Biologics, Inc.
9
0
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
11.1%
1 terminated/withdrawn out of 9 trials
87.5%
+1.0% vs industry average
0%
0 trials in Phase 3/4
86%
6 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
SYN-004 Safety and Tolerability in Allo-HCT Subjects
Role: lead
Pharmacokinetics, Safety, and Tolerability of SYN-020
Role: lead
Efficacy and Safety of SYN-010 in IBS-C
Role: collaborator
Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered SYN 020
Role: lead
A Study of the Effect of SYN-010 on Subjects With IBS-C
Role: lead
A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
Role: lead
A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy
Role: lead
A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy
Role: lead
A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C
Role: lead
All 9 trials loaded